Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTLIZBJ)

• DTT Name: Protein synthesis (hPRO synth)
• Gene Name: hPRO synth
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T77158

Molecular Interaction Atlas (MIA) of This DTT

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARV-1801	DMUMFDU	Melioidosis	1C42	Phase 2	[2]
Contezolid	DMZ0F65	MRSA infection	1D01.0Y	Phase 2	[1]
Contezolid acefosamil	DMMOHUA	Acute bacterial skin infection	1C41	Phase 2	[1]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zilascorb (2H)	DM3IRES	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [3] Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anticancer Drugs. 1997 Mar;8(3):296-303.